Moomoo AIのまとめ
AbbVie Inc., a global biopharmaceutical company, has announced the issuance of $15 billion in senior notes with varying maturities ranging from 2027 to 2064. The offering includes $2.25 billion of 4.800% senior notes due 2027, $2.5 billion of 4.800% senior notes due 2029, $2 billion of 4.950% senior notes due 2031, $3 billion of 5.050% senior notes due 2034, $750 million of 5.350% senior notes due 2044, $3 billion of 5.400% senior notes due 2054, and $1.5 billion of 5.500% senior notes due 2064. Interest on each series of notes is payable semi-annually, commencing September 15, 2024. The company plans to use the net proceeds from the sale of the notes for various corporate purposes, including repaying loans under the New Term Facility, funding the Cerevel merger consideration, repaying outstanding borrowings under the company's commercial paper program, paying related fees and expenses, and for general corporate purposes. The notes were offered through a group of underwriters led by Morgan Stanley, J.P. Morgan, BofA Securities, and Citigroup, with several other financial institutions participating as joint book-running managers and co-managers. The offering is expected to close on February 26, 2024.
AbbVie Inc., a global biopharmaceutical company, has announced the issuance of $15 billion in senior notes with varying maturities ranging from 2027 to 2064. The offering includes $2.25 billion of 4.800% senior notes due 2027, $2.5 billion of 4.800% senior notes due 2029, $2 billion of 4.950% senior notes due 2031, $3 billion of 5.050% senior notes due 2034, $750 million of 5.350% senior notes due 2044, $3 billion of 5.400% senior notes due 2054, and $1.5 billion of 5.500% senior notes due 2064. Interest on each series of notes is payable semi-annually, commencing September 15, 2024. The company plans to use the net proceeds from the sale of the notes for various corporate purposes, including repaying loans under the New Term Facility, funding the Cerevel merger consideration, repaying outstanding borrowings under the company's commercial paper program, paying related fees and expenses, and for general corporate purposes. The notes were offered through a group of underwriters led by Morgan Stanley, J.P. Morgan, BofA Securities, and Citigroup, with several other financial institutions participating as joint book-running managers and co-managers. The offering is expected to close on February 26, 2024.
グローバルなバイオ製薬会社、アッヴィは、2027年から2064年までの様々な満期を持つ150億ドルの優先債を発行することを発表しました。オファリングには、4.800％優先債＄22.5億の2027年満期、4.800％優先債＄25億の2029年満期、4.950％優先債＄20億の2031年満期、5.050％優先債＄30億の2034年満期、5.350％優先債＄750百万の2044年満期、5.400％優先債＄30億の2054年満期、5.500％優先債＄15億の2064年満期が含まれています。各シリーズの債券の利息は、2024年9月15日から半期ごとに支払われます。同社は、債券の売却から得られる純収益を、...すべて展開
グローバルなバイオ製薬会社、アッヴィは、2027年から2064年までの様々な満期を持つ150億ドルの優先債を発行することを発表しました。オファリングには、4.800％優先債＄22.5億の2027年満期、4.800％優先債＄25億の2029年満期、4.950％優先債＄20億の2031年満期、5.050％優先債＄30億の2034年満期、5.350％優先債＄750百万の2044年満期、5.400％優先債＄30億の2054年満期、5.500％優先債＄15億の2064年満期が含まれています。各シリーズの債券の利息は、2024年9月15日から半期ごとに支払われます。同社は、債券の売却から得られる純収益を、New Term Facilityのローンを返済するため、Cerevelの合併契約に資金を提供するため、同社のコマーシャルペーパープログラムの未払いの借入金を返済するため、関連する手数料や費用を支払ったり、一般企業目的に使用する予定です。このオファリングは、Morgan Stanley、J.P. Morgan、BofA Securities、Citigroupを主幹主幹事とするアンダーライタのグループを通じて提供され、いくつかの金融機関が合同主幹事として参加しました。オファリングは、2024年2月26日に終了する見込みです。
役に立った
役に立たない